QuantLogix ← ABT scorecard
📅 ABT Earnings Preview
Abbott Laboratories
Next report (est.)
October 5, 2026
Countdown
114 days
EPS growth YoY
-88.4%
Revenue growth YoY
+1.7%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
April 29, 2026 ±2.2% -2.7% under-priced
July 30, 2025 ±1.6% +0.4% over-priced
April 30, 2025 ±2.2% +0.2% over-priced
October 31, 2024 ±1.6% -0.9% over-priced
July 31, 2024 ±3.3% +0.6% over-priced
May 2, 2024 ±1.3% -0.3% over-priced
November 1, 2023 ±2.3% +0.5% over-priced
August 3, 2023 ±1.6% -1.0% over-priced
Across these reports, options implied an average ±2.0% move vs an actual average of 0.8% — the stock stayed inside the implied band 88% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q1 FY2026 $0.61 $11.2B $1.1B
Q4 FY2025 — $0 $0
Q2 FY2025 $1.01 $11.1B $1.8B
Q1 FY2025 $0.76 $10.4B $1.3B
Live 5-factor engine read: Neutral · 42/100 Full scorecard →
Get alerted before every ABT report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on ABT before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

Abbott Laboratories (ABT) reports in 114 days, with the next report estimated for October 5, 2026. Across the last 8 reports, options priced an average ±2.0% earnings move while the stock actually moved 0.8% on average — the market has systematically over-priced ABT's earnings risk. Fundamentals into the print: EPS down 88.4% year-over-year, revenue up 1.7%. QuantLogix's live 5-factor engine currently reads ABT as a neutral at 42/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →